Sarepta Therapeutics Inc (SRPT) Receives Consensus Rating of “Buy” from Brokerages

Sarepta Therapeutics Inc (NASDAQ:SRPT) has been given an average rating of “Buy” by the twenty-eight brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $187.63.

SRPT has been the subject of a number of recent analyst reports. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 4th. Citigroup initiated coverage on Sarepta Therapeutics in a research report on Tuesday, August 14th. They set a “buy” rating for the company. Bank of America initiated coverage on Sarepta Therapeutics in a research report on Friday, September 14th. They set a “buy” rating and a $199.00 target price for the company. Piper Jaffray Companies cut their target price on Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating for the company in a research report on Friday, October 26th. Finally, Cantor Fitzgerald initiated coverage on Sarepta Therapeutics in a research report on Monday, October 1st. They set an “overweight” rating and a $217.00 target price for the company.

Shares of NASDAQ:SRPT traded down $4.48 during trading on Thursday, reaching $126.49. 17,007 shares of the company traded hands, compared to its average volume of 1,031,394. The company has a market cap of $8.65 billion, a price-to-earnings ratio of -77.31 and a beta of 1.84. The company has a debt-to-equity ratio of 0.65, a quick ratio of 7.84 and a current ratio of 8.85. Sarepta Therapeutics has a 52 week low of $50.68 and a 52 week high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.29). The company had revenue of $78.49 million for the quarter, compared to the consensus estimate of $78.84 million. Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. Research analysts predict that Sarepta Therapeutics will post -4.38 EPS for the current fiscal year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $140.50, for a total value of $936,713.50. Following the completion of the transaction, the director now directly owns 126,534 shares in the company, valued at $17,778,027. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas S. Ingram bought 16,695 shares of the company’s stock in a transaction on Tuesday, October 30th. The stock was purchased at an average price of $120.39 per share, with a total value of $2,009,911.05. Following the completion of the transaction, the chief executive officer now directly owns 412,811 shares of the company’s stock, valued at approximately $49,698,316.29. The disclosure for this purchase can be found here. 7.90% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Sarepta Therapeutics by 3.3% in the third quarter. Vanguard Group Inc. now owns 5,384,899 shares of the biotechnology company’s stock valued at $869,715,000 after purchasing an additional 170,999 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Sarepta Therapeutics by 3.8% in the third quarter. Legal & General Group Plc now owns 29,239 shares of the biotechnology company’s stock valued at $4,723,000 after buying an additional 1,074 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Sarepta Therapeutics by 35.5% in the third quarter. TIAA CREF Investment Management LLC now owns 281,890 shares of the biotechnology company’s stock valued at $45,528,000 after buying an additional 73,792 shares during the period. Teachers Advisors LLC increased its stake in shares of Sarepta Therapeutics by 41.6% in the third quarter. Teachers Advisors LLC now owns 132,916 shares of the biotechnology company’s stock valued at $21,467,000 after buying an additional 39,036 shares during the period. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $3,715,000. Hedge funds and other institutional investors own 90.85% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Story: How to calculate the intrinsic value of a stock

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit